A detailed history of Silicon Valley Capital Partners transactions in Abb Vie Inc. stock. As of the latest transaction made, Silicon Valley Capital Partners holds 715 shares of ABBV stock, worth $127,548. This represents 0.02% of its overall portfolio holdings.

Number of Shares
715
Previous 721 0.83%
Holding current value
$127,548
Previous $123,000 14.63%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$163.84 - $199.33 $983 - $1,195
-6 Reduced 0.83%
715 $141,000
Q2 2024

Oct 29, 2024

SELL
$154.79 - $180.76 $6,346 - $7,411
-41 Reduced 5.38%
721 $123,000
Q1 2024

Apr 29, 2024

SELL
$159.82 - $182.1 $25,251 - $28,771
-158 Reduced 17.17%
762 $138,000
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $18,163 - $20,456
-132 Reduced 12.55%
920 $142,000
Q3 2023

Nov 03, 2023

SELL
$133.59 - $154.65 $14,026 - $16,238
-105 Reduced 9.08%
1,052 $156,000
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $13,251 - $16,490
-100 Reduced 7.96%
1,157 $155,000
Q1 2023

May 09, 2023

SELL
$144.61 - $166.54 $8,965 - $10,325
-62 Reduced 4.7%
1,257 $200,000
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $182,430 - $218,782
1,319 New
1,319 $213,000
Q2 2022

Jul 13, 2022

SELL
$137.62 - $174.96 $6,743 - $8,573
-49 Reduced 3.22%
1,475 $226,000
Q1 2022

May 13, 2022

BUY
$131.98 - $163.75 $1,055 - $1,310
8 Added 0.53%
1,524 $247,000
Q4 2021

Feb 11, 2022

BUY
$107.43 - $135.93 $162,863 - $206,069
1,516 New
1,516 $205,000
Q2 2021

Aug 11, 2021

SELL
$105.21 - $117.21 $208,105 - $231,841
-1,978 Closed
0 $0
Q1 2021

May 10, 2021

SELL
$102.3 - $112.62 $11,662 - $12,838
-114 Reduced 5.45%
1,978 $214,000
Q4 2020

Feb 16, 2021

BUY
$80.49 - $108.67 $168,385 - $227,337
2,092 New
2,092 $224,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $315B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Silicon Valley Capital Partners Portfolio

Follow Silicon Valley Capital Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silicon Valley Capital Partners, based on Form 13F filings with the SEC.

News

Stay updated on Silicon Valley Capital Partners with notifications on news.